Aztreonam
featured

    WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#: 317305

CAS#: 78110-38-0

Description: Aztreonam is a monobactam antibiotic used primarily to treat infections caused by gram-negative bacteria. Aztreonam is a monocyclic beta-lactam antibiotic originally isolated from Chromobacterium violaceum with bactericidal activity. Aztreonam preferentially binds to and inactivates penicillin-binding protein-3 (PBP-3), which is involved in bacterial cell wall synthesis, thereby inhibiting bacterial cell wall integrity and leading to cell lysis and death. This agent differs from other beta-lactam antibiotics because it is resistant to beta-lactamase hydrolysis, and it is usually used to treat infections caused by gram-negative aerobic microorganisms.


Chemical Structure

img
Aztreonam
CAS# 78110-38-0

Theoretical Analysis

MedKoo Cat#: 317305
Name: Aztreonam
CAS#: 78110-38-0
Chemical Formula: C13H17N5O8S2
Exact Mass: 435.05185
Molecular Weight: 435.43
Elemental Analysis: C, 35.86; H, 3.94; N, 16.08; O, 29.39; S, 14.73

Size Price Shipping out time Quantity
10mg USD 80 2 Weeks
25mg USD 90 2 Weeks
50mg USD 120 2 Weeks
100mg USD 150 2 Weeks
200mg USD 250 2 Weeks
500mg USD 450 2 Weeks
1g USD 750 2 Weeks
2g USD 1250 2 Weeks
5g USD 1650 2 Weeks
10g USD 2650 2 Weeks
Inquire bulk and customized quantity

Pricing updated 2021-03-03. Prices are subject to change without notice.

Aztreonam purity > 98%, is in stock. Current shipping out time is about 2 weeks after order is received. CoA, QC data and MSDS documents are available in one week after order is received.

Synonym: Aztreonam; Az threonam; Az-threonam; Azactam; Azthreonam; Aztreonam;Aztreonam Esteve Brand; Aztreonam Squibb Brand;Bristol Myers Squibb Brand of Aztreonam; Bristol-Myers Squibb Brand of Aztreonam;Esteve Brand of Aztreonam; Sanofi Winthrop Brand of Aztreonam; SQ 26,776; SQ-26,776; SQ26,776; Squibb Brand of Aztreonam; Urobactam

IUPAC/Chemical Name: 2-[(Z)-[1-(2-amino-1,3-thiazol-4-yl)-2-[[(2S,3S)-2-methyl-4-oxo-1-sulfoazetidin-3-yl]amino]-2-oxoethylidene]amino]oxy-2-methylpropanoic acid

InChi Key: WZPBZJONDBGPKJ-CAOOACKPSA-N

InChi Code: InChI=1S/C13H17N5O8S2/c1-5-7(10(20)18(5)28(23,24)25)16-9(19)8(6-4-27-12(14)15-6)17-26-13(2,3)11(21)22/h4-5,7H,1-3H3,(H2,14,15)(H,16,19)(H,21,22)(H,23,24,25)/b17-8+

SMILES Code: CC1C(C(=O)N1S(=O)(=O)O)NC(=O)C(=NOC(C)(C)C(=O)O)C2=CSC(=N2)N

Appearance:
Solid powder

Purity:
>98% (or refer to the Certificate of Analysis)

Shipping Condition:
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition:
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility:
Soluble in DMSO, not in water

Shelf Life:
>2 years if stored properly

Drug Formulation:
This drug may be formulated in DMSO

Stock Solution Storage:
0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code:
2934.99.9001

Handling Instructions:

Preparing Stock Solutions

The following data is based on the product molecular weight 435.43 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Select a batch to recalculate based on the batch molecular weight:
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL

Molarity Calculator

Calculate the mass, volume, or concentration required for a solution.
=
x
x
g/mol

*When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and SDS / CoA (available online).

Reconstitution Calculator

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.

=
÷

Dilution Calculator

Calculate the dilution required to prepare a stock solution.
x
=
x

1: Gaeta F, Valluzzi RL, Alonzi C, Maggioletti M, Caruso C, Romano A. Tolerability of aztreonam and carbapenems in patients with IgE-mediated hypersensitivity to penicillins. J Allergy Clin Immunol. 2015 Apr;135(4):972-6. doi: 10.1016/j.jaci.2014.10.011. Epub 2014 Nov 22. PubMed PMID: 25457154.

2: Singh R, Kim A, Tanudra MA, Harris JJ, McLaughlin RE, Patey S, O'Donnell JP, Bradford PA, Eakin AE. Pharmacokinetics/pharmacodynamics of a β-lactam and β-lactamase inhibitor combination: a novel approach for aztreonam/avibactam. J Antimicrob Chemother. 2015 Sep;70(9):2618-26. doi: 10.1093/jac/dkv132. Epub 2015 May 29. PubMed PMID: 26024868.

3: Schechter MS, Trueman D, Farquharson R, Higuchi K, Daines CL. Inhaled aztreonam lysine versus inhaled tobramycin in cystic fibrosis. An economic evaluation. Ann Am Thorac Soc. 2015 Jul;12(7):1030-8. doi: 10.1513/AnnalsATS.201312-453OC. PubMed PMID: 26053185.

4: Barker AF, O'Donnell AE, Flume P, Thompson PJ, Ruzi JD, de Gracia J, Boersma WG, De Soyza A, Shao L, Zhang J, Haas L, Lewis SA, Leitzinger S, Montgomery AB, McKevitt MT, Gossage D, Quittner AL, O'Riordan TG. Aztreonam for inhalation solution in patients with non-cystic fibrosis bronchiectasis (AIR-BX1 and AIR-BX2): two randomised double-blind, placebo-controlled phase 3 trials. Lancet Respir Med. 2014 Sep;2(9):738-49. doi: 10.1016/S2213-2600(14)70165-1. Epub 2014 Aug 18. PubMed PMID: 25154045.

5: Crandon JL, Nicolau DP. Human simulated studies of aztreonam and aztreonam-avibactam to evaluate activity against challenging gram-negative organisms, including metallo-β-lactamase producers. Antimicrob Agents Chemother. 2013 Jul;57(7):3299-306. doi: 10.1128/AAC.01989-12. Epub 2013 May 6. PubMed PMID: 23650162; PubMed Central PMCID: PMC3697389.

6: Hutchinson D, Barclay M, Prescott WA, Brown J. Inhaled aztreonam lysine: an evidence-based review. Expert Opin Pharmacother. 2013 Oct;14(15):2115-24. doi: 10.1517/14656566.2013.831070. Epub 2013 Aug 31. Review. PubMed PMID: 23992352.

7: Hansen C, Skov M. Evidence for the efficacy of aztreonam for inhalation solution in the management of Pseudomonas aeruginosa in patients with cystic fibrosis. Ther Adv Respir Dis. 2015 Feb;9(1):16-21. Review. PubMed PMID: 25471692.

8: Assael BM, Pressler T, Bilton D, Fayon M, Fischer R, Chiron R, LaRosa M, Knoop C, McElvaney N, Lewis SA, Bresnik M, Montgomery AB, Oermann CM; AZLI Active Comparator Study Group.. Inhaled aztreonam lysine vs. inhaled tobramycin in cystic fibrosis: a comparative efficacy trial. J Cyst Fibros. 2013 Mar;12(2):130-40. doi: 10.1016/j.jcf.2012.07.006. Epub 2012 Sep 15. PubMed PMID: 22985692.

9: Oguri T, Ishii Y, Shimizu-Ibuka A. Conformational Change Observed in the Active Site of Class C β-Lactamase MOX-1 upon Binding to Aztreonam. Antimicrob Agents Chemother. 2015 Aug;59(8):5069-72. doi: 10.1128/AAC.04428-14. Epub 2015 Jun 8. PubMed PMID: 26055361; PubMed Central PMCID: PMC4505233.

10: Wang X, Zhang F, Zhao C, Wang Z, Nichols WW, Testa R, Li H, Chen H, He W, Wang Q, Wang H. In vitro activities of ceftazidime-avibactam and aztreonam-avibactam against 372 Gram-negative bacilli collected in 2011 and 2012 from 11 teaching hospitals in China. Antimicrob Agents Chemother. 2014;58(3):1774-8. doi: 10.1128/AAC.02123-13. Epub 2013 Dec 16. PubMed PMID: 24342639; PubMed Central PMCID: PMC3957831.

11: Estep PM, Ferreira JA, Dupree LH, Aldridge PJ, Jankowski CA. Impact of an antimicrobial stewardship initiative to evaluate β-lactam allergy in patients ordered aztreonam. Am J Health Syst Pharm. 2016 Mar 1;73(5 Suppl 1):S8-13. doi: 10.2146/ajhp150440. PubMed PMID: 26896530.

12: Zeitler K, Salvas B, Stevens V, Brown J. Aztreonam lysine for inhalation: new formulation of an old antibiotic. Am J Health Syst Pharm. 2012 Jan 15;69(2):107-15. doi: 10.2146/ajhp100624. Review. PubMed PMID: 22215356.

13: Buonomo A, Nucera E, De Pasquale T, Pecora V, Lombardo C, Sabato V, Colagiovanni A, Rizzi A, Aruanno A, Pascolini L, Patriarca G, Schiavino D. Tolerability of aztreonam in patients with cell-mediated allergy to β-lactams. Int Arch Allergy Immunol. 2011;155(2):155-9. doi: 10.1159/000318844. Epub 2010 Dec 22. PubMed PMID: 21196760.

14: Corey GR, Wilcox M, Talbot GH, Friedland HD, Baculik T, Witherell GW, Critchley I, Das AF, Thye D. Integrated analysis of CANVAS 1 and 2: phase 3, multicenter, randomized, double-blind studies to evaluate the safety and efficacy of ceftaroline versus vancomycin plus aztreonam in complicated skin and skin-structure infection. Clin Infect Dis. 2010 Sep 15;51(6):641-50. doi: 10.1086/655827. PubMed PMID: 20695801.

15: Ye Q, Ding W, Rinaldi F, Huang Y, Miller SA, Bolgar M. Structural characterization of low level degradants in aztreonam injection and an innovative approach to aid HPLC method validation. J Pharm Biomed Anal. 2016 May 30;124:358-64. doi: 10.1016/j.jpba.2016.03.017. Epub 2016 Mar 9. PubMed PMID: 26991056.

16: Pesaturo KA, Horton ER, Belliveau P. Inhaled aztreonam lysine for cystic fibrosis pulmonary disease-related outcomes. Ann Pharmacother. 2012 Jul-Aug;46(7-8):1076-85. doi: 10.1345/aph.1Q653. Epub 2012 Jul 3. Review. PubMed PMID: 22764322.

17: Guglani L, Abdulhamid I, Ditouras J, Montejo J. Desensitization to inhaled aztreonam lysine in an allergic patient with cystic fibrosis using a novel approach. Ann Pharmacother. 2012 Oct;46(10):e25. doi: 10.1345/aph.1R293. Epub 2012 Sep 25. PubMed PMID: 23012384.

18: Whitaker P, Etherington C, Williams K, Conway S, Peckham D. The use of nebulised aztreonam lysine (AZLI) in aztreonam hypersensitive patients. J Cyst Fibros. 2012 Jul;11(4):353. doi: 10.1016/j.jcf.2012.01.007. Epub 2012 Feb 16. PubMed PMID: 22341263.

19: Tunkel AR, Scheld WM. Aztreonam. Infect Control Hosp Epidemiol. 1990 Sep;11(9):486-94. Review. PubMed PMID: 2230052.

20: O'Sullivan BP, Yasothan U, Kirkpatrick P. Inhaled aztreonam. Nat Rev Drug Discov. 2010 May;9(5):357-8. doi: 10.1038/nrd3170. PubMed PMID: 20431562.